Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma
Background: Pancreatic ductal adenocarcinoma (PC) is an aggressive form of cancer treated with chemotherapy regimens such as leucovorin, 5-fluorouracil (5-FU), irinotecan, oxaliplatin (FOLFIRINOX), and gemcitabine plus albumin-bound paclitaxel (nab-Paclitaxel). Maintenance chemotherapy is increasing...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-04-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251321894 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850196437731639296 |
|---|---|
| author | Jordan Powell Alexa F. Viniotis Chase Irwin Gayle S. Jameson Lana Caldwell Erkut H. Borazanci |
| author_facet | Jordan Powell Alexa F. Viniotis Chase Irwin Gayle S. Jameson Lana Caldwell Erkut H. Borazanci |
| author_sort | Jordan Powell |
| collection | DOAJ |
| description | Background: Pancreatic ductal adenocarcinoma (PC) is an aggressive form of cancer treated with chemotherapy regimens such as leucovorin, 5-fluorouracil (5-FU), irinotecan, oxaliplatin (FOLFIRINOX), and gemcitabine plus albumin-bound paclitaxel (nab-Paclitaxel). Maintenance chemotherapy is increasingly being studied as an option for patients with a prior response to chemotherapy, prolonged stable disease, and those unable to tolerate the toxicities of traditional chemotherapy. Objective: Our retrospective analysis aims to evaluate the effectiveness and tolerability of capecitabine as maintenance therapy in patients with PC. Design: Thirty-three patients treated for PC with capecitabine (an oral formulation of 5-FU) maintenance therapy at our single institution between 8/01/2013 and 9/02/2021 were identified on chart review via the electronic medical record (EMR). Methods: Kaplan–Meier curves were fit to evaluate patient progression-free survival (PFS) and overall survival (OS). Results: Thirty-three individuals were identified: 21 males and 12 females, with a median age of 69 years. Fifteen of 33 had stage IV PC. Nineteen had progression of disease; 8 completed therapy and transitioned to observation or other treatments; 2 did not tolerate treatment; and 4 were still undergoing treatment. The median PFS was 13.01 months (396.0 days), and the median OS was 28.42 months (865.0 days). Conclusion: Maintenance with capecitabine seems safe and may represent a valuable option in patients with advanced PC controlled using FOLFIRINOX or gemcitabine/nab-Paclitaxel induction treatment. |
| format | Article |
| id | doaj-art-5bcc171b523f41d88369716a0eb3ec22 |
| institution | OA Journals |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-5bcc171b523f41d88369716a0eb3ec222025-08-20T02:13:27ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-04-011710.1177/17588359251321894Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinomaJordan PowellAlexa F. ViniotisChase IrwinGayle S. JamesonLana CaldwellErkut H. BorazanciBackground: Pancreatic ductal adenocarcinoma (PC) is an aggressive form of cancer treated with chemotherapy regimens such as leucovorin, 5-fluorouracil (5-FU), irinotecan, oxaliplatin (FOLFIRINOX), and gemcitabine plus albumin-bound paclitaxel (nab-Paclitaxel). Maintenance chemotherapy is increasingly being studied as an option for patients with a prior response to chemotherapy, prolonged stable disease, and those unable to tolerate the toxicities of traditional chemotherapy. Objective: Our retrospective analysis aims to evaluate the effectiveness and tolerability of capecitabine as maintenance therapy in patients with PC. Design: Thirty-three patients treated for PC with capecitabine (an oral formulation of 5-FU) maintenance therapy at our single institution between 8/01/2013 and 9/02/2021 were identified on chart review via the electronic medical record (EMR). Methods: Kaplan–Meier curves were fit to evaluate patient progression-free survival (PFS) and overall survival (OS). Results: Thirty-three individuals were identified: 21 males and 12 females, with a median age of 69 years. Fifteen of 33 had stage IV PC. Nineteen had progression of disease; 8 completed therapy and transitioned to observation or other treatments; 2 did not tolerate treatment; and 4 were still undergoing treatment. The median PFS was 13.01 months (396.0 days), and the median OS was 28.42 months (865.0 days). Conclusion: Maintenance with capecitabine seems safe and may represent a valuable option in patients with advanced PC controlled using FOLFIRINOX or gemcitabine/nab-Paclitaxel induction treatment.https://doi.org/10.1177/17588359251321894 |
| spellingShingle | Jordan Powell Alexa F. Viniotis Chase Irwin Gayle S. Jameson Lana Caldwell Erkut H. Borazanci Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma Therapeutic Advances in Medical Oncology |
| title | Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma |
| title_full | Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma |
| title_fullStr | Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma |
| title_full_unstemmed | Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma |
| title_short | Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma |
| title_sort | retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma |
| url | https://doi.org/10.1177/17588359251321894 |
| work_keys_str_mv | AT jordanpowell retrospectiveanalysisofcapecitabinemaintenancetherapyinpancreaticductaladenocarcinoma AT alexafviniotis retrospectiveanalysisofcapecitabinemaintenancetherapyinpancreaticductaladenocarcinoma AT chaseirwin retrospectiveanalysisofcapecitabinemaintenancetherapyinpancreaticductaladenocarcinoma AT gaylesjameson retrospectiveanalysisofcapecitabinemaintenancetherapyinpancreaticductaladenocarcinoma AT lanacaldwell retrospectiveanalysisofcapecitabinemaintenancetherapyinpancreaticductaladenocarcinoma AT erkuthborazanci retrospectiveanalysisofcapecitabinemaintenancetherapyinpancreaticductaladenocarcinoma |